Overview
RLAY market data
Price History
RLAY price chart · 1M
- O
- 19.99
- H
- 20.12
- L
- 19.22
- C
- 19.51
- Vol
- 227,713.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $19.99
- Previous Close
- $20.58
- Day High
- $20.12
- Day Low
- $19.22
- 52 Week High
- $21.15
- 52 Week Low
- $9.15
- 7 Day Return
- -6.07%
- 30 Day Return
- +4.75%
- 90 Day Return
- +40.53%
- 1 Year Return
- +97.12%
- Daily Notional Volume
- $4.4M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.61 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,047.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.43 – $21.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.4B · P/B 2.59 · P/S 422.40.
Company News
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29Benzinga · Aug 20, 2026, 11:42 AM
JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31Benzinga · Aug 14, 2026, 4:13 PM
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26Benzinga · Aug 10, 2026, 1:11 PM
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30Benzinga · Aug 7, 2026, 6:58 PM
Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K EstimateBenzinga · Aug 6, 2026, 8:18 PM
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31Benzinga · Jul 21, 2026, 12:45 PM
Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29Benzinga · Jul 16, 2026, 10:05 AM
8-K filing — Relay Therapeutics, Inc. (RLAY)SEC EDGAR · Jun 9, 2026, 8:35 PM